Allergan Forays into Liver Diseases with Acquisitions of Tobira and Akarna
By Subham Nandi
Pharma Deals Review: Vol 2016 Issue 9 (Table of Contents)
Published: 30 Sep-2016
DOI: 10.3833/pdr.v2016.i9.2198 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Continuing its flurry of M&A activity, Allergan has made a bold entry into the non-alcoholic steatohepatitis (NASH) market with the complementary acquisitions of Tobira Therapeutics and Akarna Therapeutics...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS